All product information provided is intended for the European Union audience only. These products may not be available in all Member States of the EU, or in countries outside the EU or may be available under a different trademark; in different strengths; or for different indications. Countries outside the EU may have different regulatory requirements that would call for different information to be available.
We have granted licenses under our proprietary technologies to enable third parties to develop, commercialize and, in some cases, manufacture products for which we receive royalties and/or manufacturing revenues. Such arrangements in the European Union include the following:
*RISPERDAL CONSTA, TREVICTA and XEPLION, Janssen products, utilize Alkermes’ proprietary extended-release microsphere technology, proprietary technology and proprietary nanoparticle injectable extended-release technology, respectively.
BYDUREON® is a registered trademark of AstraZeneca Pharmaceuticals LP. FAMPYRA® is a registered trademark of Acorda Therapeutics, Inc. RISPERDAL CONSTA®, TREVICTA® and XEPLION® are registered trademarks of Johnson & Johnson.
This page is intended for the EU audience only.